Calithera Biosciences, Inc.
CALADrugs in Pipeline
8
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
CB-839
Advanced Renal Cell Carcinoma
Telaglenestat (CB-839)
Solid Tumors
Sapanisertib
Breast Cancer
TAK-228
Renal Cell Carcinoma
Glutaminase Inhibitor CB-839
Colorectal Cancer
Fulvestrant
Breast Neoplasms
everolimus
Clear Cell Renal Cell Carcinoma
Paclitaxel
Triple Negative Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CB-839 | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
Telaglenestat (CB-839) | Phase 2 | Solid Tumors | - | - |
Sapanisertib | Phase 2 | Breast Cancer | - | - |
TAK-228 | Phase 2 | Renal Cell Carcinoma | - | - |
Glutaminase Inhibitor CB-839 | Phase 2 | Colorectal Cancer | - | - |
Fulvestrant | Phase 2 | Breast Neoplasms | - | - |
everolimus | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
Paclitaxel | Phase 2 | Triple Negative Breast Cancer | - | - |
Frequently asked questions
What is in Calithera Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Calithera Biosciences, Inc.'s (CALA) pipeline across Phase 2. Its lead program is CB-839 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Calithera Biosciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Calithera Biosciences, Inc. (CALA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CALA biotech catalysts?→
Add CALA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Calithera Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.